Stock Analysis of CTi Biopharma Corp (CTIC) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code CTIC
Close 9.09
Change 0 / 0 %
Volume 11387.83 K
Vol Change 9497.35 K / 502.38 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthBullish
Growth Index Poor Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Poor Stability Stock


Fundamental View of CTi Biopharma Corp
PE (TTM)

-13.95

Very Poor
Price / Book

-58.23

Very Poor
Price / Sales

14.29

Very Poor
Piotroski F Score

5.0

Indecisive
Market Cap

1198.79 M

Enterprise Value

1216.31 M

ROA (TTM)

-61.83

Very Poor
ROE (TTM)

0

Poor
Net Margin (TTM)

-102.43

Very Poor
Revenue

%

53948.00 K
Net Profit

5.02 %

-92992.00 K
Debt to Equity

-2.73

Very Poor
Altman Z Score

-24.48

Very Poor
Quick Ratio

1.22

Indecisive
Cash Ratio

0.985

Not Good


Highs/Lows of CTi Biopharma Corp
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week9.07 0.221 % 1.58 % 9.19.0723-Jun-2320-Jun-23
Two Week9.05 0.442 % 2.92 % 9.19.06523-Jun-2312-Jun-23
One Month8.99 1.11 % 3.52 % 9.18.9823-Jun-2324-May-23
Three Month4.3 111.40 % 5.46 % 9.14.0123-Jun-2306-Apr-23
Six Months5.63 61.46 % 15.09 % 9.14.0123-Jun-2306-Apr-23
One year5.96 52.52 % 24.22 % 9.14.0123-Jun-2306-Apr-23
Two year2.33 290.13 % 45.41 % 9.11.4323-Jun-2302-Dec-21
Five year5.08 78.94 % 88.14 % 9.10.600123-Jun-2324-Dec-18
Ten year12.2 25.49 % 180.53 % 42.50.600121-Jan-1424-Dec-18


Technical View of CTi Biopharma Corp
RSI

83.62

Mild Bearish
MACD

0.389

Bearish
ADX

74.52

Strong Bullish
Super Trend

8.96

Mild Bullish
Williams %R

-14.29

Mild Bearish
CCI

112.16

Mild Bearish


EMA 5

9.09

Bullish
EMA 15

9.00

Bullish
EMA 50

7.82

Bullish
EMA 100

6.86

Bullish
SMA 100

6.15

Bullish
SMA 200

5.87

Strong Bullish
SMA 5 / 20

9.09 / 9.06

Bullish
SMA 15 / 50

9.07 / 7.44

Bullish
SMA 50 / 200

7.44 / 5.87

Strong Bullish




Charts of CTi Biopharma Corp


Returns of CTi Biopharma Corp with Peers
Period / StockCTICFDMTMIRMAUTL
1 Week0.221%4.01%3.39%12.50%
1 Mth1.11%-8.23%4.52%14.50%
3 Mth111.40%-19.54%-7.99%-21.05%
6mth61.46%42.26%-25.07%-9.46%
1 Year52.52%6.97%-8.51%55.71%
2 Year290.13%305.32%35.56%100.00%
5 Years78.94%---70.80%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of CTi Biopharma Corp with Peers
Ratio / StockCTICFDMTMIRMAUTL
PE-13.95-2188.62-1712.22-3.78
P/B-58.23650.791370.783.05
ROA-61.83-27.49-28.65-42.65
ROE0-29.74-195.55-80.74
Debt To Equity-2.730.01021.220.0453
Revenue53948.00 K
% 		21989.00 K
602.75 % 		144726 K
87.80 % 		5523.00 K
10.83 %
Net Income-92992.00 K
5.02 % 		-95933.00 K
10.76 % 		-164187.00 K
21.02 % 		-158163.00 K
6.26 %


Technicals of CTi Biopharma Corp with Peers
Technical / StockCTICFDMTMIRMAUTL-
ADX74.529.3015.3417.28
CMF0.0445-0.03170.1750.065
MFI33.5945.5762.2866.53
RSI83.6245.0652.8557.18
MACD Abv SignalFalseFalseTrueTrue
Price Above 50 MATrueFalseTrueTrue-
Price Above 200 MATrueTrueFalseFalse-


About : CTi Biopharma Corp

Address : 3101 Western Avenue, Seattle, WA, United States, 98121
Tel : 206 282 7100
URL : https://www.ctibiopharma.com
Code : CTIC, ISIN : US12648L6011, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 21_Mar_1997
Employee Count : 127

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.


Note : All Data Generated at the End of Trading Hours (EOD Data)